<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364850">
  <stage>Registered</stage>
  <submitdate>28/08/2013</submitdate>
  <approvaldate>25/09/2013</approvaldate>
  <actrnumber>ACTRN12613001075774</actrnumber>
  <trial_identification>
    <studytitle>Stimulation Therapy to Produce Tears for the Treatment of Dry Eye</studytitle>
    <scientifictitle>Neurostimulation to Increase Tear Production Measured Objectively via Schirmer Test in Adult Patients with Mild to Severe Dry Eye Disease - Pilot Study</scientifictitle>
    <utrn>U1111-1146-7736</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dry eye disease</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Normal eye development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1 - Neurostimulation device (EMS 2000) - Lacrimal gland neurostimulation.  The current provided is approximately 1 milliamp with the patient controlling the amplitude with a knob.  The recommended duration of treatment is approximately 30 seconds and the recommended treatment frequency is four times per day or as needed.  The duration of the intervention period is 6 months.

Patient diaries are used to monitor adherence to the intervention.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean Schirmer test score compared to baseline</outcome>
      <timepoint>At 6 months after start of study treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse events - Possible adverse events can include headache, pain/discomfort, and nosebleed, all assessed through case history.</outcome>
      <timepoint>At 6 months after start of study treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Ocular Surface Disease Index score compared to baseline</outcome>
      <timepoint>At 6 months after start of study treatment </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean dry eye symptoms as assessed by a Visual Analogue Scale compared to baseline</outcome>
      <timepoint>At 6 months after start of study treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Willing to sign the informed consent and deemed capable of following the study protocol

Basal Schirmer tear test of less than or equal to 15 mm; Schirmer test at least twice or at least 10 mm higher after nasal stimulation with cotton swab

Baseline Ocular Surface Disease Index score of at least 13  

Normal lid anatomy, blinking function and closure
 
Corrected visual acuity of 20/200 (Snellen equivalent) or better in each eye
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Individuals with a history or presence of any systemic disorder or condition that is not stabilized or would likely interfere with the interpretation of study results or subject safety

Presence of severe systemic allergy or acute or chronic rhinitis or sinusitis 

Individuals with the presence or history of any ocular disorder or condition that would likely interfere with the interpretation of study results or subject safety 

Nasal, orbital or lacrimal trauma, surgery, tumour or cancer

Significant corneal or conjunctival scarring of any aetiology

Known hypersensitivity to one of the components of the study device or procedural medications 

Patients with a history of chronic or recurrent epistaxis

Participation in any clinical trial with a new active substance or a new device during the past 3 months 

Women who are pregnant, planning a pregnancy or nursing at study entry
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Prospective</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>A statistical comparison of treatment to baseline data will be analyzed.  Data will be tested for normality.  Data will be analyzed using descriptive statistics and/or using typical statistical analyses for normally distributed data sets (e.g. ANOVA, Tukeys multiple comparison test, Students t-test, etc.).  Appropriate transformations or tests will be utilized for non-normally distributed data.  Additional statistical tests (e.g. binomial probability tests, etc.) may be used as needed.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>21/05/2013</anticipatedstartdate>
    <actualstartdate>21/05/2013</actualstartdate>
    <anticipatedenddate>31/03/2014</anticipatedenddate>
    <actualenddate>7/02/2014</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>41</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>22/12/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Baja California</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Oculeve, Inc.</primarysponsorname>
    <primarysponsoraddress>395 Oyster Point Blvd.
Suite 501
South San Francisco, CA 94080 USA </primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Oculeve, Inc.</fundingname>
      <fundingaddress>395 Oyster Point Blvd.
Suite 501
South San Francisco, California 94080 USA </fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to demonstrate that neurostimulation increases tear production and improves symptoms of dry eye disease over baseline measurements.  </summary>
    <trialwebsite />
    <publication>Friedman NJ, Butron K, Robledo N, Loudin J, Baba SN, Chayet A. A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. Clin Ophthalmol 2016;10:795-804.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862385/
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>CODET Vision Institute Comite de Investigacion y Etica</ethicname>
      <ethicaddress>Ave Padre Kino 10159
Zona Rio, Tijuana, B.C.  C.P. 22320
</ethicaddress>
      <ethicapprovaldate>10/05/2013</ethicapprovaldate>
      <hrec>SSA Junio 09, 2009</hrec>
      <ethicsubmitdate>1/05/2013</ethicsubmitdate>
      <ethiccountry>Mexico</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Arturo Chayet, MD</name>
      <address>CODET Vision Institute
Av Padre Kino No. 10159
Zona Rio, Tijuana, BC 22320
</address>
      <phone>+52 664 9792020</phone>
      <fax>+52 664 6824096</fax>
      <email>martha.federico@codetvision.com  </email>
      <country>Mexico</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Daniel Hamilton</name>
      <address>Oculeve Inc. 
395 Oyster Point Boulevard 
Suite 501
South San Francisco, CA 94080, USA </address>
      <phone>1 415 5806236</phone>
      <fax>+1 650 7370200</fax>
      <email>dan@oculeve.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Arturo Chayet, MD</name>
      <address>CODET Vision Institute
Av Padre Kino No. 10159
Zona Rio, Tijuana, BC 22320</address>
      <phone>+52 664 9792020</phone>
      <fax>+52 664 6824096</fax>
      <email>martha.federico@codetvision.com  </email>
      <country>Mexico</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Jasmine Wilson</name>
      <address>Oculeve, Inc. 
395 Oyster Point Boulevard 
Suite 501 
South San Francisco, CA 94080 USA </address>
      <phone>+1 415 580 6246</phone>
      <fax>+1 650 7370200</fax>
      <email>jasmine@oculeve.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>